Interlace Trial
Induction chemotherapy followed by chemoradiotherapy significantly improves both progression-free survival and overall survival in patients with locally advanced cervical cancer compared to chemoradiotherapy alone.
Study Summaries
COMPASSION 16
Cadonilimab potentially offers better PFS than pembrolizumab and atezolizumab therapies in recurrent advanced metastatic cervical cancer
GOG 241: Phase III Randomized Trial in Patients with Mucinous Epithelial Ovarian Cancer
Neither oxaliplatin-capecitabine nor bevacizumab significantly improved OS or PFS compared to paclitaxel-carboplatin in advanced-stage mucinous ovarian cancer.
GOG 205: Radiation for Locally Advanced Vulvar Cancer
The combination of radiation therapy with weekly cisplatin chemotherapy is effective in achieving high complete clinical and pathological response rates with manageable toxicity for the treatment of locally-advanced vulvar carcinoma.
Prospective Phase II Trial of Levonorgestrel Intrauterine Device
GOG 173: Sentinel LND in Vulvar Cancer
MILO/ENGOT-ov11: Binimetinib in Recurrent Low-Grade Serous
In low-grade serous ovarian cancer, Binimetinib did not significantly improve PFS compared to standard of care chemotherapy.
SOC-1
Surgery did not improve overall survival, but it showed a benefit in certain analyses. This supports the potential efficacy of secondary cytoreduction in specialized centers and for selected patients.
AURELIA Trial: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer
Adding bevacizumab to chemotherapy significantly improves PFS and ORR in patients with platinum-resistant recurrent ovarian cancer.
OCEANS Trial: Bevacizumab Maintenance in Platinum Sensitive Recurrence
- Adding bevacizumab to gemcitabine and carboplatin significantly improves PFS but no difference in OS in platinum-sensitive recurrence